We believe that, with clinical research, proton therapy will likely become the cancer treatment of choice for many patients. The future of proton therapy depends heavily on clinical research over the coming years. That’s why our primary mission is to conduct clinical research to improve the effectiveness and availability of proton therapy.

Most of the studies conducted at the UF Health Proton Therapy Institute are based on the expectation that at least one outcome of treatment will be significantly better than what can be achieved with traditional radiation therapy.

UF Health Proton Therapy Institute

Current clinical trials: 

Proton therapy research focuses on a number of areas and types of cancer, including pediatric malignancies, lymphoma, eye malignancies and disorders, and cancers of the central nervous system, head and neck, breast, pancreas and urological and pulmonary systems – as well as sarcomas.

There are no breast cancer clinical trials open for enrollment at this time.

There are no Central Nervous System clinical trials open for enrollment at this time.

There are no Chordomas and/or Chondrosarcomas clinical trials open for enrollment at this time.

There are no Head and Neck Cancer clinical trials open for enrollment at this time.

There are no lung cancer clinical trials open for enrollment at this time.

There are no Lymphoma clinical trials open for enrollment at this time.

Study title:

The University of Florida Health Proton Therapy Institute (UFHPTI) Radiation Oncology Outcome Tracking Project (RADTRAC-JAX)

Principal Investigator:

Nancy P. Mendenhall, MD

Why is this study being done?

The purpose of this study is to collect information from you and your medical records regarding your disease, your treatment, and your side effects to see what effects the radiation has on you and your disease.

Contact us for additional Information on this trial.

Study title:

PAN009-18 (PC04): A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma

Principal Investigator:

R. Charles Nichols, MD

Why is this study being done?

The purpose of this study is to find out what effects, good and/or bad, proton radiation combined with chemotherapy and surgery, if performed, has on you and your pancreatic cancer. The goal is improved disease free survival. This study will look at the side effects from the treatment and the quality of your life in relation to your treatment experience. It will also look at how the tumor responds to the combination of treatment with proton radiation.

Contact us for additional Information on this trial.

1st Study title:

Proton and Photon Consortium Registry (PPCR)

Local Principal Investigator:

Daniel J. Indelicato, MD

Why is this study being done?

The purpose of this registry is to collect demographic information (like age, race, gender, zip code) and clinical data (such as diagnosis, treatments and side effects) of pediatric patients who receive proton therapy.

Contact us for additional Information on this trial.

1st Study title:

GU010-18 (PR06): Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

Principal Investigator:

Randal H. Henderson, MD, MBA

Why is this study being done?

The purpose of this study is to evaluate the safety and effectiveness of proton radiation therapy for patients who have undergone radical prostatectomy.

Contact us for additional Information on this trial.

2nd Study title:

PARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life; A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Principal Investigator:

Dr. Nancy P. Mendenhall, MD

Why is this study being done?

The purpose of this study is to compare two types of radiation therapies called proton beam therapy (PBT) and Intensity Modulated Radiation Therapy (IMRT) as treatments for prostate cancer. In particular, we are studying whether men being treated for prostate cancer have the same amount of side effects from either one of the two different radiation treatments.

Contact us for additional Information on this trial.

3rd Study title:

UF1712-PR11: A Phase II Study of Dose-Escalated Proton-Based Radiation Therapy. Delivered with a Simultaneous Integrated Boost (SIB) to Intraprostatic Tumors (IPT) Visible on Pretreatment Magnetic Resonance Image

Principal Investigator:

Curtis Bryant, MD, MPH

Why is this study being done?

The purpose of this research study is to determine if dose-escalated proton radiation therapy will improve disease control for patients with high-risk prostate cancer while minimizing possible toxicity (side effects).

Previous studies have shown an advantage for delivering higher radiation doses for prostate cancer when looking at overall disease control outcomes. This study features hypofractionation (radiation delivered with a higher daily dose) and an extra boost of radiation to the prostate tumor seen on pretreatment imaging as a method of delivering higher radiation doses for high-risk prostate cancers.

Contact us for additional Information on this trial.

4th Study title:

COMPPARE: A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

Principal Investigator:

Dr. Nancy P. Mendenhall, MD

Why is this study being done?

Two types of radiation treatment are routinely used for prostate cancer: photon (X-ray) therapy and proton therapy. The purpose of the overall study is to directly compare the two therapies to determine which one has better disease control and fewer patientreported and doctor-reported side effects. In addition, this study includes a randomized study to determine if hypofractionated proton therapy is as good as standard fractionated proton therapy. Hypofractionation is when radiation therapy is given over a shorter period of time with a higher dose per treatment (fraction) than standard radiation therapy.

Contact us for additional Information on this trial.

5th Study title:
RadTox II: Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly from Plasma

Principal Investigator:
Randal H. Henderson, MD, MBA

Why is this study being done?
The purpose of this study is to see if the RadTox test can predict the degree of negative reaction or unwanted side effects a person will have from radiation treatment during the early course of radiation treatment and by comparing the degree of unwanted side effects.

Contact us for additional Information on this trial.

There are no Sarcoma clinical trials open for enrollment at this time.

There are no Skin clinical trials open for enrollment at this time.

UF Health Proton Therapy Institute Waiting Area

Didn’t find your answer?

Contact Us  

Request more information about clinical trials.

Click here